HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MYL-1501D

Networked: 5 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barve, Abhijit: 5 articles (06/2021 - 01/2018)
2.	Aubonnet, Patrick: 4 articles (06/2021 - 01/2019)
3.	Sun, Bin: 4 articles (06/2021 - 01/2018)
4.	Raiter, Yaron: 3 articles (06/2021 - 01/2019)
5.	Blevins, Thomas C: 3 articles (01/2020 - 01/2018)
6.	Donnelly, Charles: 2 articles (06/2021 - 01/2020)
7.	Athalye, Sandeep: 2 articles (01/2020 - 01/2019)
8.	Muniz, Rafael: 2 articles (01/2020 - 01/2019)
9.	Ankersen, Michael: 2 articles (01/2019 - 01/2018)
10.	Bowsher, Ronald R: 1 article (06/2021)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/26/2021 - "The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials. " 01/01/2020 - "Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study." 01/01/2018 - "Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study." 06/26/2021 - "In INSTRIDE 1, patients with type 1 diabetes received MYL-1501D or insulin glargine over a 52-week period. " 06/26/2021 - "In INSTRIDE 1 and INSTRIDE 2, similar immunogenicity profiles were observed for MYL-1501D and reference insulin glargine in patients with type 1 diabetes and type 2 diabetes, respectively. "
2.	Type 2 Diabetes Mellitus (MODY) 06/26/2021 - "The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials. " 01/01/2019 - "Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study." 06/26/2021 - "In INSTRIDE 1 and INSTRIDE 2, similar immunogenicity profiles were observed for MYL-1501D and reference insulin glargine in patients with type 1 diabetes and type 2 diabetes, respectively. " 01/01/2019 - "INSTRIDE 2 was a multicentre, open-label, randomized, parallel-group, phase III non-inferiority study comparing the efficacy and safety of MYL-1501D with those of reference insulin glargine in insulin-naive and insulin-non-naive patients with type 2 diabetes mellitus receiving oral antidiabetic drugs (OADs). " 06/26/2021 - "In INSTRIDE 2, patients with type 2 diabetes treated with oral antidiabetic drugs, insulin naive or not, received MYL-1501D or reference insulin glargine over a 24-week period. "
3.	Diabetes Mellitus 06/26/2021 - "Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies."

Related Drugs and Biologics

1.	Insulin Glargine (Lantus)
2.	Biosimilar Pharmaceuticals
3.	Insulin (Novolin)
4.	Hypoglycemic Agents (Hypoglycemics)